Dermapharm Holding SE
ISIN: DE000A2GS5D8
WKN: A2GS5D
27 June 2024 06:15PM

EQS-News: Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share

Dermapharm Holding SE · ISIN: DE000A2GS5D8 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1935093

Price (EoD) at the time of publication (27.06.2024): €36,00 | Last price update: €34,70 (30.08.2024)

EQS-News: Dermapharm Holding SE / Key word(s): AGM/EGM
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share

27.06.2024 / 18:15 CET/CEST
The issuer is solely responsible for the content of this announcement.


Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share

  • 2024 outlook confirmed
  • Board of Management and Supervisory Board actions ratified with large majority
  • Shareholders resolve dividend payment of EUR 0.88 per share
  • Distribution ratio: approximately 78% of consolidated net profit

Grünwald, 27 June 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today held its Annual General Meeting for financial year 2024. 90.3% of the share capital was in attendance at the Annual General Meeting, which was held in person. The majority of shareholders approved the management's proposals under every agenda item.

The Annual General Meeting ratified the actions of all members of the Board of Management and of the Supervisory Board for financial year 2023 with a 98.6% and 91.5% majority of votes cast, respectively. The Annual General Meeting acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.88 per share carrying dividend rights. The total distribution amounts to EUR 47.4 million, representing a distribution ratio of approximately 78% of the distributable consolidated net income.

Grant Thornton AG Wirtschaftsprüfungsgesellschaft was re-elected as the auditor for the current financial year. RSM Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft was chosen as auditor for the sustainability reporting. The detailed results of the voting for each agenda item are available in the Annual General Meeting section of the Company website https://ir.dermapharm.de.

In their retrospective on financial year 2023, the Board of Management and Supervisory Board emphasised the particular strength and resilience of the corporate strategy. Dermapharm succeeded in maintaining its growth trajectory despite a difficult macroeconomic environment and the scheduled end of vaccine production. The Board of Management and the Supervisory Board expressed their special thanks to the entire workforce for their extraordinary dedication and commitment. The Board of Management concluded by providing an outlook for the remainder of financial year 2024.

"We have used 2023 to make the company fit for the future. The investment in the acquisition of Arkopharma and Montavit is a booster for our internationalisation. With targeted investments in photovoltaics and energy efficiency improvements, for example, we are able to reduce costs and offer our customers a sustainable supply of pharmaceuticals made in Europe," said Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.

Based on the course of business to date in 2024, the Board of Management confirms the guidance for 2024 and expects consolidated revenue of EUR 1,170–1,210 million and adjusted consolidated EBITDA of EUR 305–315 million.

Company profile

Dermapharm – Pharmaceutical Excellence "Made in Europe"

Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Germany, the rest of Europe and the United States.

In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,300 marketing authorisations with more than 400 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company's integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its "Other healthcare products" segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for herbal food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the "Parallel import business" segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently the sixth largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.

Contact

Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 – 64186-233

E-mail: ir@dermapharm.com



27.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1935093

 
End of News EQS News Service

1935093  27.06.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1935093&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024e 2025e
Sales1 700,88 793,83 942,91 1.024,78 1.135,35 1.200,00 0,00
EBITDA1,2 168,53 184,52 354,07 344,87 287,48 312,00 0,00
EBITDA-Margin3 24,05 23,24 37,55 33,65 25,32 26,00 0,00
EBIT1,4 119,51 136,85 298,47 243,69 182,89 205,00 0,00
EBIT-Margin5 17,05 17,24 31,65 23,78 16,11 17,08 0,00
Net Profit (Loss)1 77,81 85,93 208,90 132,62 60,53 107,00 0,00
Net-Margin6 11,10 10,83 22,16 12,94 5,33 8,92 0,00
Cashflow1,7 100,61 131,10 250,37 288,53 219,42 240,00 0,00
Earnings per share8 1,43 1,59 3,89 2,49 1,16 1,95 2,30
Dividend per share8 0,80 0,88 2,17 1,05 0,88 0,95 1,05
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Grant Thornton

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Dermapharm Holding
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A2GS5D DE000A2GS5D8 SE 2.156,29 Mio € 09.02.2018 Kaufen 8FWH3H74+2J
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
15,83 24,52 0,65 22,26 4,02 9,83 1,90
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
1,05 0,88 0,95 2,37%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
26.06.2025 15.05.2025 26.08.2025 14.11.2024 28.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,63%
40,05 €
ATH 91,95 €
+13,94% +14,77% +2,96% -0,96% +43,04%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL